Showing results (21-30 of 219) with videos related to
Sort By:
Pageof 22
British Journal of Cancer|September 1, 1996
Delivering cancer care: a model from the West MidlandsD J Kerr, R Griffiths, B EdwardsCancer Letters|February 1, 1991
Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequencesV Zoumpourlis, D J Kerr, D A SpandidosAnticancer Research|November 1, 1991
The effect of doxorubicin, daunorubicin and 4'-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukemia cellsA Eliopoulos, D J Kerr, D A SpandidosBiochemical Pharmacology|February 4, 1992
Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequencesV Zoumpourlis, D J Kerr, D A SpandidosExpert Opinion on Biological Therapy|July 26, 2003
Gene therapy for colorectal cancerD J Kerr, L W Seymour, F MarutaCancer Chemotherapy and Pharmacology|January 1, 1987
Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in manJ Cummings, D J Kerr, S B KayeAnti-Cancer Drugs|December 1, 1991
The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cellsA Eliopoulos, D J Kerr, D A SpandidosClinical Pharmacokinetics|July 31, 1999
Can pharmacokinetic monitoring improve clinical use of fluorouracil?A M Young, S Daryanani, D J KerrBritish Journal of Cancer|April 1, 1993
Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicinJ A Plumb, W Luo, D J KerrAnti-Cancer Drugs|February 1, 1993
Differential interaction of cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell lineV Zoumpourlis, D J Kerr, D A SpandidosPageof 22